Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.

AMD Clinical Trial

— REVERS  

Official title:

A PILOT STUDY TO EVALUATE THE PROGRESSION OF THE DISEASE AND RESPONSE TO SUPPLEMENTATION WITH POSTBIOTICS IGEN-0222 IN PATIENTS WITH MACULAR DEGENERATION

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05056025
• Other study ID #: 2020/79-MIN-HUGC
• Status: Recruiting
• Phase: N/A
• Start date: December 2, 2020
• Est. completion date: January 2024

Study information

• Verified date: September 2021
• Source: Institut de la Macula y la Retina
• Contact: Jordi Mones, MD PhD
• Phone: +34 935 950 155
• Email: jmones[@]institutmacula.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A pilot study to establish the efficacy and safety of supplementation with postbiotics in patients with macular degeneration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: January 2024
• Est. primary completion date: January 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Subjects of either gender aged 50 years or older with high risk intermediate AMD defined as the following criteria: >4 areas of at least iRORA or iORA (incomplete RPE and outer retinal atrophy and incomplete outer retinal atrophy). 1 area of cRORA + 2 > areas of iRORA. < 1 mm2 of cRORA (complete RPE and outer retinal atrophy). No exudative neovascular AMD. Exclusion Criteria: Best corrected visual acuity in the study eye less than 20/400 by ETDRS. Not ability to provide written informed consent. Not ability to return for all trial visits. if subject cannot attend all trial required visits. GA secondary to any condition other than specified. Any ocular condition in the study eye that would progress during the study that could affect central vision or otherwise be a confounding factor. Concomitant treatment with any ocular or systemic medication that is known to be toxic to the lens, retina or optic nerve. Anti -VEGF therapy is allowed in Cohort B. Presence of intraocular inflammation (= trace cell or flare), macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-retinal traction maculopathy, vitreous hemorrhage or aphakia (pseudophakia with or without an intact capsule is not an exclusion criteria). Presence of idiopathic or autoimmune-associated uveitis in either eye. Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, fundus photography or fundus autofluorescence. Subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the following year. Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication. History of any of the following procedures: Posterior vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant or retinal detachment. Previous therapeutic radiation in the region of the study eye. Any treatment with an investigational agent in the past 60 days for any condition. Pregnant or nursing women. Additionally, women with childbearing potential must be using at least two effective contraception methods.

Related Conditions & MeSH terms

• AMD
• Drusen Stage Macular Degeneration
• Macular Degeneration
• Reticular Pseudodrusen
• Retinal Drusen

Intervention

Dietary Supplement:
• Postbotics and Vitamins
2 capsule 3 times a day, before meals
• Vitamins
2 capsule 3 times a day, before meals

Locations

Country	Name	City	State
Spain	Institut de la Macula	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Institut de la Macula y la Retina	Igen BioLab SLU

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microperimetry	Median change difference in the % reduced threshold in microperimetry	12 months
Primary	Color vision change	Median change in red/green and yellow/blue color thresholds	12 months
Secondary	Average Threshold microperimetry	Mean change of Average Threshold microperimetry	12 months
Secondary	Best corrected visual acuity (BCVA)	Mean Change of Best corrected visual acuity (BCVA)	12 months
Secondary	Low luminance visual acuity (LLVA)	Mean Change of Low luminance visual acuity (LLVA)	12 months
Secondary	Rod and cone sensitivity	Mean change of Rod and cone sensitivity test	12 months
Secondary	Advanced Vision and Optometric Test (AVOT)	Mean change AVOT vision test	12 months
Secondary	incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) conversion loci	Number of scans within the optical coherence tomography OCT cube as as per protocol (Spectralis OCT cube protocol: 20º x 20ª, 97b-scan, high-resolution, 62 microns between scans centered at the fovea) with features of iRORA2 conversion loci (change from baseline to 12 months of iRORA loci).	12 months
Secondary	complete retinal pigment epithelial and outer retinal atrophy (cRORA) conversion loci	Number of scans within the OCT cube as as per protocol with of features of cRORA (change from baseline to 12 months of cRORA loci).	12 months
Secondary	Area of cumulative cRORA conversion	Area of cumulative cRORA conversion as measured in mm2 by en face OCT projection scans of the OCT cube as as per protocol	12 months
Secondary	Hyperreflective dots(HRD)+ (retinal pigment epithelium)RPE defects areas conversion	Number of scans within the OCT cube as as per protocol with HRD+RPE defects areas conversion (change from baseline to 12 months of HRD+RPE defects)	12 months
Secondary	Change in outer nuclear layer (ONL) volume	Change in outer nuclear layer (ONL) volume measured by the spectralis software after manually correction of the layer segmentation	12 months
Secondary	Change of drusen > 100 microns height	Change of number of drusen of > 100 microns height measured by OCT within the OCT cube as as per protocol	12 months
Secondary	Change of subretinal drusenoid deposits (SDD) through ellipsoid zone (ELZ)	Change of number of subretinal drusenoid deposits (SDD) through ellipsoid zone within the OCT cube as as per protocol	12 months
Secondary	Change of SDD ribbon	Change of number SDD ribbon within the OCT cube as as per protocol	12 months
Secondary	Conversion to choroidal neovascularization (CNV)	Any conversion to any type of macular neovascularization (MNV) within the OCT cube as as per protocol 1 as per OCT features of leakage, and/or intrarretinal, subretinal or subRPE fluid, and/or presence of Subretinal hyperreflective material(SHRM)	12 months